Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That H… (NCT02193282) | Clinical Trial Compass
Active — Not RecruitingPhase 3
Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial)
United States, Puerto Rico390 participantsStarted 2015-02-11
Plain-language summary
This phase III ALCHEMIST trial studies how well erlotinib hydrochloride compared to observation works in treating patients with stage IB-IIIA non-small cell lung cancer that has been completely removed by surgery (resected). Erlotinib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Who can participate
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
. Patient registered to A151216 and the assessment performed centrally by the protocol-specified laboratory
. By a local Clinical Laboratory Improvement Amendments (CLIA) certified laboratory; the report must indicate the result as well as the CLIA number of the laboratory that performed the assay; these patients will also have been registered to A151216, but can be enrolled on A081105 regardless of the central lab results
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1This trial is testing erlotinib after surgery for Stage IB–IIIA non-small cell lung cancer — my cancer was removed completely, so is my situation similar enough that my doctor thinks this kind of approach could be relevant to my case?
2Since this is a Phase 3 trial measuring overall survival, what does that mean about how much is already known about whether erlotinib actually helps people live longer after surgery compared to not taking it?
3This trial specifically requires a certain type of tumor mutation — am I likely to need genetic testing of my tumor to even be considered, and have those results already been done or is that something we'd need to arrange?
4The trial is no longer enrolling new patients — does that mean there are results or data already available that my doctor could look at to help guide whether erlotinib after surgery might still be worth discussing as part of my treatment plan?
5Are there standard-of-care options or other completed trials for post-surgical treatment of my stage of non-squamous non-small cell lung cancer that my doctor would want me to consider before or instead of a targeted therapy like erlotinib?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Overall survival (OS)
Timeframe: The time from randomization until death, assessed up to 10 years